| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Indatuximab Ravtansine
CAS:1238517-16-2
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Indatuximab Ravtansine
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Indatuximab (DHD30801)
CAS:1238517-16-2
Purity:PAGE:>95% Package:100ug;1mg
|
| Company Name: |
Wuhan Jingkangen Biomedical Technology Co., Ltd
|
| Tel: |
13720134139 086-15871494362 13720134139 |
| Email: |
orders@jknbiochem.com |
| Products Intro: |
Product Name:Indatuximab Ravtansine
CAS:1238517-16-2
Purity:95% Package:100ug:500ug:1mg
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:Indatuximab
CAS:1238517-16-2
Purity:95% Package:1mg;5mg
|
|
| | Indatuximab Ravtansine Basic information |
| | Indatuximab Ravtansine Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Indatuximab Ravtansine Usage And Synthesis |
| Uses | Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities[1]. | | in vivo | Indatuximab ravtansine (5.3-21.2 mg/kg; i.v.; once) inhibits multiple myeloma tumour growth in vivo and improves host survival[1]. | Animal Model: | SCID mice inoculated with MOLP-8 multiple myeloma xenografts[1] | | Dosage: | 5.3 mg/kg, 10.6 mg/kg or 21.2 mg/kg | | Administration: | i.v.; once | | Result: | Inhibited multiple myeloma tumour growth in vivo and improved host survival. |
| | References | [1] Kurt Schnfeld, et al. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. J Hematol Oncol. 2017 Jan 11;10(1):13. DOI:10.1186/s13045-016-0380-0 |
| | Indatuximab Ravtansine Preparation Products And Raw materials |
|